ArticleDermatology practical & conceptual2026
Biologic Treatment in Elderly Patients with Psoriasis: Focus on Safety and Adherence.
Article in Dermatology practical & conceptual, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-World Use of Biologic Therapy in Elderly Patients with Moderate-to-Severe Psoriasis: A Retrospective Single-Center Study.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe number of elderly psoriasis patients is increasing, yet data on biological treatments in this population remains limited.
objectivesTo evaluate the characteristics, efficacy, and safety of biologics in psoriasis patients aged ≥65 years and identify factors contributing to treatment interruption or discontinuation.
methodsThe study included psoriasis patients aged ≥65 years who had received at least one biological treatment at a tertiary center for a minimum of 24 weeks between 2022 and 2024. Demographic and clinical data, treatment history, PASI scores, adverse events, and reasons for treatment interruption or discontinuation were evaluated.
resultsAmong 231 patients on biologics, 43 (18.6%) were aged ≥65 years (mean age: 70.2 ± 4.8 years, male-to-female ratio: 2:1). Mean PASI scores improved from 14.5 ± 8.8 at baseline to 1.5 ± 1.5 at weeks 12-16, and to 0.83 ± 1.2 at week 52. Latent tuberculosis and anti-HBc positivity were common (65.1% and 51.2%, respectively), but no reactivation occurred. Adverse events were reported in 39.5% of patients, most commonly infections (27.9%). Treatment-ending events occurred in 7.0%, all due to malignancies. Treatment interruptions occurred in 20.9%, mainly due to noncompliance, transportation difficulties, and comorbidities. Notably, 20.9% of the patients required assistance to attend their hospital visits, and 44.2% required help administering their drug. Treatment was discontinued in 16.3%, primarily due to malignancies and secondary failure.
conclusionsBiologics are effective in psoriasis patients aged ≥65 years. A relatively high malignancy rate emphasizes the importance of age-appropriate screening. Noncompliance, comorbidities, transportation problems, and healthcare access barriers may pose challenges in long-term treatment maintenance.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.